Innate Pharma (IPHA) Operating Expenses (2019 - 2025)
Innate Pharma's (IPHA) quarterly Operating Expenses came in at -$73.3 million in Q4 2025, up 4.26% YoY from -$70.4 million in Q4 2024, and down 113.95% on a QoQ basis from -$34.3 million in Q2 2025.
Innate Pharma (IPHA) Operating Expenses (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 7 years of Operating Expenses data on file, last reported at -$73.3 million in Q4 2025.
- Quarterly Operating Expenses rose 4.26% year-over-year to -$73.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$225.9 million (up 6.82% YoY) and the FY2025 annual result came in at $73.3 million, down 4.26% from the prior year.
- Operating Expenses eased to -$73.3 million in Q4 2025, from -$34.3 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of -$34.3 million in Q2 2025 to a low of -$83.0 million in Q4 2021.
- A 5-year average of -$59.8 million and a median of -$61.4 million in 2021 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses climbed 20.06% — and 2023, when it decreased 11.68%.
- Tracing IPHA's Operating Expenses over 5 years: stood at -$83.0 million in 2021, then advanced by 8.88% to -$75.6 million in 2022, then fell by 5.76% to -$80.0 million in 2023, then grew by 4.18% to -$76.6 million in 2024, then climbed by 4.26% to -$73.3 million in 2025.
- The last three Operating Expenses figures came in at -$73.3 million (Q4 2025), -$34.3 million (Q2 2025), and -$76.6 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 541.02 Mn |
| 10 | Innate Pharma | 198.00 Mn | 198.00 Mn | - | -73.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -73.35 Mn |
| Jun 30, 2025 | -34.28 Mn |
| Dec 31, 2024 | -76.61 Mn |
| Jun 30, 2024 | -41.63 Mn |
| Dec 31, 2023 | -79.95 Mn |
| Jun 30, 2023 | -44.21 Mn |
| Dec 31, 2022 | -75.60 Mn |
| Jun 30, 2022 | -39.58 Mn |
| Dec 31, 2021 | -82.97 Mn |
| Jun 30, 2021 | -49.51 Mn |
| Dec 31, 2020 | -81.90 Mn |
| Jun 30, 2020 | -50.66 Mn |
| Dec 31, 2019 | -115.83 Mn |
| Jun 30, 2019 | -51.55 Mn |